News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Johnson & Johnson (JNJ) Faces Inquiries Into Marketing of Two Other Drugs as Older Probes Nears



8/7/2012 7:07:33 AM

Johnson & Johnson faces fresh government inquiries about its marketing practices, even as the health-care giant works to finalize a potentially costly settlement of long-running U.S. probes of its promotion of the antipsychotic Risperdal and other drugs. J&J's Janssen Pharmaceuticals unit in April received a letter from the U.S. Justice Department requesting documents related to the marketing and promotion of the antibiotic Doribax, J&J disclosed in its quarterly report filed last week with the Securities and Exchange Commission.

Read at Market Watch
Read at News Release
Read at News Release
Read at Wall Street Journal


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES